Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GeneFerm Biotechnology Co's Enterprise Value is NT$1,345.8 Mil.
GeneFerm Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$75.9 Mil. Therefore, GeneFerm Biotechnology Co's EV-to-FCF for today is 17.73.
The historical rank and industry rank for GeneFerm Biotechnology Co's EV-to-FCF or its related term are showing as below:
ROCO:1796'
s EV-to-FCF Range Over the Past 10 Years
Min: -2418.94 Med: -19.59 Max: 1237.65
Current: 17.95
During the past 13 years, the highest EV-to-FCF of GeneFerm Biotechnology Co was 1237.65. The lowest was -2418.94. And the median was -19.59.
ROCO:1796's EV-to-FCF is ranked better than 57.35% of 565
companies
in the Drug Manufacturers industry
Industry Median: 20.96
vs ROCO:1796: 17.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GeneFerm Biotechnology Co (ROCO:1796) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GeneFerm Biotechnology Co's PE Ratio (TTM) for today is calculated as:
GeneFerm Biotechnology Co's share price for today is NT$31.40.
GeneFerm Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.710.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
GeneFerm Biotechnology Co EV-to-FCF Related Terms
GeneFerm Biotechnology Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, GeneFerm Biotechnology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneFerm Biotechnology Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GeneFerm Biotechnology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where GeneFerm Biotechnology Co's EV-to-FCF falls into.
GeneFerm Biotechnology Co's current Enterprise Value is NT$1,345.8 Mil.
GeneFerm Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$75.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneFerm Biotechnology Co (ROCO:1796) has a EV-to-FCF of 17.73 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on GeneFerm Biotechnology Co and its competitors. According to the industry distribution chart, GeneFerm Biotechnology Co ranks #241 out of 565 companies in the Drug Manufacturers industry, placing it in the top 42.7%.
Is GeneFerm Biotechnology Co's EV-to-FCF too high?
GeneFerm Biotechnology Co's current EV-to-FCF is 17.73. The Drug Manufacturers industry median EV-to-FCF is 20.96. GeneFerm Biotechnology Co's value of 17.73 is 15.4% below this industry median. Based on the distribution chart, GeneFerm Biotechnology Co ranks #241 out of 565 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GeneFerm Biotechnology Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GeneFerm Biotechnology Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GeneFerm Biotechnology Co ranks #241 out of 565 companies for EV-to-FCF. This puts GeneFerm Biotechnology Co in the upper half of its industry. The industry median EV-to-FCF is 20.96. GeneFerm Biotechnology Co's value of 17.73 is 15.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneFerm Biotechnology Co's current EV-to-FCF of 17.73 is 15.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on GeneFerm Biotechnology Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneFerm Biotechnology Co's current EV-to-FCF is 17.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneFerm Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co (ROCO:1796) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.04, compared to a current price of NT$31.40 — trading 46.8% below its estimated fair value. The current EV-to-FCF is 17.73 and 15.4% below the Drug Manufacturers industry median of 20.96. GeneFerm Biotechnology Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For GeneFerm Biotechnology Co (ROCO:1796), the current EV-to-FCF is 17.73 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneFerm Biotechnology Co (ROCO:1796) Overvalued in 2026?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co stock appears to be undervalued.
The current stock price of NT$31.40 is trading 46.8% below its estimated GF Value™ of NT$59.04.
GuruFocus considers GeneFerm Biotechnology Co to be Significantly Undervalued.
Key valuation signals for ROCO:1796:
EV-to-FCF: 17.73
GF Value™: NT$59.04 vs. price of NT$31.40 (46.8% below fair value)
Industry Position: 15.4% below the Drug Manufacturers median (#241 of 565)
No single metric tells the full story. See the ROCO:1796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneFerm Biotechnology Co Ltd is a fermentation company based in Taiwan. It is engaged in manufacturing health food and supplements which include Fermented Microbial products, Fermented Fungi products, Probiotics and Extraction, and Concentration products among others.
65GF Score
Get the complete analysis for ROCO:1796
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1796 has been successfully added to your 
